Chaotic talks show challenge of reaching opioid settlement
By Thursday, half of the nation’s state attorneys general said they would reject a tentative deal crafted by the other half, and many criticized the terms as grossly insufficient.
Pharmaceutical
Articles
UPDATE: Tentative opioids settlement falls short of nationwide deal
A tentative settlement announced Wednesday over the role Purdue Pharma played in the nation’s opioid addiction crisis falls short of the far-reaching national settlement the OxyContin maker had been seeking for months, with litigation sure to continue.
Lilly’s hot-selling Taltz approaching blockbuster status
Last year, Taltz rang up sales of $937.5 million, and doctors are increasingly prescribing it. For the first six months of this year, Taltz recorded $606.3 million in sales, putting it on pace to break the $1 billion threshold, perhaps in the third quarter.
Opioid settlement would divide money based on local impact
The formulas would take into account several factors, including opioid distribution in a given jurisdiction, the number of people who misuse opioids and the number of overdose deaths.
Doctors don’t always know what patients will owe for meds
While the price of almost any good or service can be found online, most Americans don’t know what they’ll owe for a prescription medication until they get it.
Purdue Pharma in talks to settle for billions in opioid lawsuits
Drugmaker Purdue Pharma is negotiating a multibillion-dollar settlement with lawyers for local and state governments that would resolve about 2,000 lawsuits against the company.
Feds shortchanged Indiana $175M over 2 years in fighting opioid epidemic, report says
Indiana accounted for 4% of the nation’s opioid-related deaths, but received just 1.9% of the nation’s $11 billion opioid-related funding awarded to states over the past two years, according to the new study.
Brand-name drug prices rising at slower pace, lower amounts
After years of frequent list price hikes, many drugmakers are showing some restraint, according to the analysis of drug prices.
Trump’s Canada drug import plan can’t happen without Big Pharma
President Donald Trump’s plan to import cheap Canadian drugs overlooks a crucial fact: Canada’s pharmaceutical supply chain is beholden to the drugmakers.
U.S. to set up plan allowing prescription meds from Canada
The Trump administration said Wednesday it will create a pathway allowing Americans to legally and safely import lower-cost prescription drugs from Canada for the first time, reversing years of opposition from federal health authorities.
Pfizer’s blockbuster deal with Myland expected to reshape drug industry
The new publicly traded company will have sales of about $19 billion to $20 billion in 2020, the drugmakers said in a statement.
Trump meets with drug industry lobby as pricing bill advances
The meeting occurred as a bipartisan effort is underway in the Senate that two of its sponsors say would lead to $100 billion in savings on prescription-drug spending over a decade.
Senators unveil compromise to reduce drug costs for seniors
Iowa Republican Charles Grassley and Oregon Democrat Ron Wyden said the bill would for the first time limit drug copays for people with Medicare’s “Part D” prescription plan, by capping patients’ out-of-pocket costs.
Many companies contributed to U.S. opioid crisis, new figures show
Records kept by the federal Drug Enforcement Administration show that 76 billion oxycodone and hydrocodone pills—the vast majority of them generics, not brand names—were shipped to U.S. pharmacies from 2006 to 2012.
Number of U.S. overdose deaths appears to be falling
U.S. overdose deaths last year likely fell for the first time in nearly three decades, preliminary statistics suggest.
J&J accused of dodging liability for ‘cunning’ opioid drug push
The trial in Oklahoma City is the first of more than 1,900 local U.S. government lawsuits against drug makers and distributors over the fallout from opioid abuse.
Elanco in merger talks with pharmaceutical giant Bayer, sources say
The multibillion-dollar merger would combine Elanco, the fourth-largest global player in animal health, with Bayer’s pet-health division, which ranks fifth in veterinary medicine, Reuters reported. The combination would create a dominant force in the industry.
Judge strikes down rule requiring drug ads to reveal prices
Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.
Groups protest insulin prices outside Lilly headquarters
Several diabetes and health care advocacy groups on Thursday announced a seven-figure fundraising campaign to help fund their fight against what they consider “skyrocketing” insulin prices.
Lilly’s push into pain research starting to pay off
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.